Evidence map›Paper›PMID 32420163›Full record

ArticleTranslational andrology and urology2020

A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation.

Guanghui Li, Junjie Ma, Lu Xu, Jiali Fang, Lei Zhang, Jialin Wu, Xingqiang Lai, Luhao Liu, Yunyi Xiong, Wei Yin and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Guanghui LiDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Junjie MaDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Lu XuDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Jiali FangDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Lei ZhangDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Jialin WuDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Xingqiang LaiDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Luhao LiuDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Yunyi XiongDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Wei YinDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Tao ZhangDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Peng ZhangDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Li LiDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Rongxin ChenDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Jiao WangDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Zheng ChenDepartment of Organ Transplantation, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Second Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo explore the safety and efficacy of direct antiviral therapy in patients with hepatitis C virus (HCV) infection after renal transplantation.

methodsWe retrospectively reviewed the medical information of 15 cases of HCV

resultsA total of 15 patients were enrolled in the study. All patients turned HCV-RNA negative after 12 weeks of direct-antiviral therapy; the serological test of all patients demonstrated an 100% response rate in rapid virological response (RVR) (15/15), 12-week sustained virological response (SVR12), and 24-week sustained virological response (SVR24). In addition, compared to pre-treatment, the liver function within 12, 24, and 48 weeks after treatment was significantly improved. Moreover, eGFR, CREA, and anti-rejection drug concentration remained stable while acute rejection reaction and other obvious side effects were not observed throughout the treatment period.

conclusionsThe direct antiviral therapy was well-tolerated and effective for patients with chronic hepatitis C after renal transplantation.

Indexed as

chronic hepatitis Cdirect antiviral drugsRenal transplantationvirological response

Identifiers

PMID32420163
PMCPMC7215012
OpenAlexW3013641939

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.